Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years

Authors not listed

Alachua Government Services, Inc. · 2013

Abstract

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2013). An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years. <em>Alachua Government Services, Inc.</em>. https://clinicaltrials.gov/study/NCT01911754
Vancouver
Anonymous. An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years. Alachua Government Services, Inc.. 2013.
BibTeX
@misc{anon2013AnOpen, title = {An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years}, author = {Anonymous}, journal = {Alachua Government Services, Inc.}, year = {2013}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings